How to Get Evenity (Romosozumab) in South Dakota

What Romosozumab Is and Why Access Matters

Romosozumab is a monoclonal antibody that inhibits sclerostin, a protein produced by osteocytes that suppresses bone formation. By blocking sclerostin, romosozumab produces a dual effect: it stimulates new bone formation while simultaneously reducing bone resorption. No other approved osteoporosis drug achieves both actions at once.

The FDA approved Evenity in April 2019 for postmenopausal women at high risk of fracture, defined as a history of osteoporotic fracture, multiple risk factors for fracture, or failure of or intolerance to other osteoporosis therapies (FDA label). The approval carried a boxed warning regarding potential increased risk of myocardial infarction, stroke, and cardiovascular death, restricting its use in patients who have had a heart attack or stroke within the preceding year.

In the ARCH trial (N=4,093), published in the New England Journal of Medicine, romosozumab reduced new vertebral fractures by 48% compared to alendronate at 24 months. The FRAME trial (N=7,180) showed a 73% reduction in new vertebral fractures versus placebo at 12 months (Cosman et al., NEJM 2016). These numbers explain the growing demand for the drug, and why patients in rural states like South Dakota often struggle with access logistics.

South Dakota has 67 counties spread across 77,116 square miles. The state has roughly 12 board-certified endocrinologists. That ratio creates a bottleneck for patients needing specialist-level osteoporosis care, making telehealth and primary-care prescribing pathways especially relevant.

Who Can Prescribe Evenity in South Dakota

Any physician (MD or DO) licensed in South Dakota can prescribe romosozumab. The drug carries no REMS (Risk Evaluation and Mitigation Strategy), so it does not require a special certification or restricted-distribution program.

Nurse practitioners in South Dakota have had full practice authority since 2017 under SDCL 36-9A, meaning NPs can independently diagnose, prescribe, and manage osteoporosis treatment without physician oversight after completing a collaborative agreement period. Physician assistants may also prescribe Evenity under their supervising physician's delegation.

In practice, most romosozumab prescriptions originate from endocrinologists, rheumatologists, or orthopedic surgeons who manage fragility fractures. Primary care physicians can prescribe it, but many defer to specialists because of the cardiovascular boxed warning, the injectable administration, and the complexity of prior authorization paperwork.

The American Association of Clinical Endocrinology (AACE) 2020 guidelines recommend romosozumab as a first-line option for patients at "very high" fracture risk, defined as a recent fracture (within 2 years), fractures while on approved therapy, very low T-scores (below −3.0), high FRAX probability, or fall-related risk factors. If your provider is unfamiliar with these criteria, sharing the AACE algorithm may help support the conversation.

Telehealth Access to Romosozumab in South Dakota

South Dakota permits telehealth prescribing for romosozumab. State law does not require an in-person visit before a provider can issue a prescription via telemedicine, provided the prescriber establishes a legitimate provider-patient relationship through a synchronous audio-video encounter.

This matters for patients in western South Dakota, where driving to the nearest endocrinologist in Rapid City or Sioux Falls may require a 4-to-6 hour round trip. A telehealth consultation can handle the initial evaluation, lab review, and prescription. The patient then receives injections either at a local infusion center, a visiting nurse, or via self-administration training (though Evenity uses prefilled syringes that require two simultaneous injections per dose, which some patients find challenging alone).

Out-of-state telehealth providers can treat South Dakota patients as long as they hold an active South Dakota medical license or practice under the Interstate Medical Licensure Compact, of which South Dakota is a member state. Several national osteoporosis-focused telehealth practices serve South Dakota patients, though patients should confirm their specific insurer's telehealth coverage policies before scheduling.

Required Labs Before Starting Evenity

Before prescribing romosozumab, clinicians in South Dakota (and everywhere else) need a defined set of baseline laboratory and imaging studies. Skipping these risks a denied prior authorization and delayed treatment.

Required baseline labs include:

• Serum calcium (corrected for albumin). Romosozumab is contraindicated in hypocalcemia. The FDA label requires correction of hypocalcemia before initiation.
• 25-hydroxyvitamin D level. Deficiency (below 20 ng/mL) should be repleted before starting therapy. The Endocrine Society recommends a target of 30 ng/mL or above for patients on anti-resorptive or anabolic therapy (Holick et al., JCEM 2011).
• Serum creatinine and eGFR. Romosozumab was studied primarily in patients with eGFR above 30 mL/min. Data in severe renal impairment are limited, and hypocalcemia risk increases with declining kidney function.
• DEXA scan (dual-energy X-ray absorptiometry). A T-score at the hip or lumbar spine is the primary diagnostic criterion. Most insurers require a T-score of −2.5 or below, or −1.0 to −2.5 with a qualifying fracture history, for prior authorization approval.
• Complete metabolic panel, including phosphorus and alkaline phosphatase.

Optional but clinically useful:

• P1NP (procollagen type 1 N-terminal propeptide), a bone formation marker. It rises sharply within the first month of romosozumab therapy and can confirm drug response. A study in the Journal of Bone and Mineral Research found that P1NP increased by a median of 145% at month one (McClung et al., JBMR 2014).
• CTX (C-terminal telopeptide), a bone resorption marker, which decreases during romosozumab therapy.

Labs can be drawn at any Quest Diagnostics, Sanford Health laboratory, Avera Health facility, or independent lab in South Dakota. Results are typically available within 2 to 5 business days.

Prior Authorization in South Dakota: What to Expect

Almost every payer requires prior authorization for romosozumab. The drug costs approximately $1,825 per monthly dose at average wholesale price, which amounts to $21,900 for the full 12-month course. Insurers want documentation before approving that expenditure.

Typical prior authorization requirements:

1. Confirmed diagnosis of postmenopausal osteoporosis with high fracture risk.
2. DEXA scan results with T-score at or below −2.5 at the lumbar spine, femoral neck, or total hip.
3. Documentation of prior fracture (vertebral, hip, or other osteoporotic fracture), or a FRAX 10-year probability exceeding the National Osteoporosis Foundation intervention thresholds (20% for major osteoporotic fracture or 3% for hip fracture).
4. Trial and failure (or documented intolerance) of at least one bisphosphonate. Many commercial plans require this step-therapy criterion. Some also require failure of denosumab.
5. Cardiovascular risk assessment documenting no MI or stroke within the past 12 months.
6. Current serum calcium level within normal range.

South Dakota Medicaid does not cover Evenity as of 2026. Patients on Medicaid may pursue an exception request, but approval is uncommon. Alternatives for Medicaid patients include teriparatide (Forteo) or abaloparatide (Tymlos), both of which may have Medicaid formulary placement depending on the managed care organization.

Medicare Part B covers Evenity under the buy-and-bill model. The physician purchases the drug, administers it in-office, and bills Medicare. Prior authorization through Medicare Administrative Contractors (MACs) applies. In South Dakota, the MAC is Wisconsin Physicians Service (WPS), which processes Part B claims for the J-8 jurisdiction. Typical turnaround for a standard prior authorization decision is 7 to 14 business days. Urgent requests can be processed in 24 to 72 hours.

Commercial insurance (Sanford Health Plan, Avera Health Plans, BCBS of South Dakota, UnitedHealthcare) varies widely. Sanford Health Plan, the largest regional insurer, generally follows AACE guidelines for coverage criteria. Expect a turnaround of 5 to 15 business days. Appeals after initial denial succeed in roughly 40% to 60% of cases when supported by specialist documentation and peer-to-peer review.

How to Fill the Prescription: Specialty Pharmacy Options

Romosozumab is dispensed through specialty pharmacies. It is not stocked at standard retail pharmacies like Walgreens or Lewis Drug. The drug requires cold-chain storage (refrigerated at 2°C to 8°C) and ships in insulated packaging with temperature monitors.

South Dakota patients typically fill Evenity prescriptions through one of these pathways:

National specialty pharmacies that ship to South Dakota addresses: Accredo (Express Scripts), OptumRx Specialty, CVS Specialty, Biologics by McKesson, and Amgen's own specialty distribution partners. Shipping is overnight or two-day with cold packs. Most arrive within 3 to 7 business days after prior authorization approval.

In-office buy-and-bill through the prescribing physician's clinic. This is the most common model for Medicare Part B patients. The clinic orders the drug from a specialty distributor (McKesson, AmerisourceBergen, or Cardinal Health), stores it in a medication-grade refrigerator, and administers it during the office visit. The clinic bills Medicare or the insurer directly.

503A compounding pharmacies in South Dakota are state-licensed and operational, but they are not relevant for romosozumab. Evenity is a biologic monoclonal antibody manufactured through recombinant DNA technology. It cannot be compounded by a 503A or 503B pharmacy. Patients searching for "compounded romosozumab" should understand that no legitimate compounding alternative exists for this molecule.

Each Evenity dose consists of two 105 mg/1.17 mL prefilled syringes administered as two separate subcutaneous injections in the abdomen, thigh, or upper arm. Both injections must be given within the same clinical visit, within 30 minutes of removal from refrigeration.

Timeline from Consultation to First Injection

Patients frequently ask how long the entire process takes. A realistic timeline for a South Dakota resident:

Week 1: Initial consultation (in-person or telehealth). Provider reviews history, orders labs and DEXA scan if not already completed within the past 12 to 24 months.

Weeks 2 to 3: Lab results return. DEXA scan completed (wait times for DEXA in rural SD can be 1 to 4 weeks depending on facility availability). Provider submits prior authorization.

Weeks 3 to 5: Prior authorization decision. Standard timelines are 7 to 14 business days for Medicare, 5 to 15 for commercial. If denied, a peer-to-peer review adds another 5 to 10 business days.

Week 5 to 6: Specialty pharmacy ships the first dose, or the clinic orders stock for buy-and-bill administration. First injection administered.

Total elapsed time from initial consultation to first injection: approximately 4 to 8 weeks. Patients with a recent DEXA scan and labs already on file may compress this to 3 to 4 weeks.

Cost, Copay Assistance, and Financial Navigation

The wholesale acquisition cost of romosozumab is roughly $1,825 per monthly dose. Without insurance, the full 12-dose course approaches $22,000.

Amgen offers the Evenity Access and Reimbursement Program for eligible patients. The program includes copay assistance cards that can reduce out-of-pocket costs to as low as $0 per dose for commercially insured patients, with a maximum annual benefit that varies by calendar year. Medicare and Medicaid beneficiaries are not eligible for manufacturer copay cards due to federal Anti-Kickback Statute restrictions.

For uninsured or underinsured patients, Amgen's Safety Net Foundation provides free drug to qualifying individuals based on household income (generally at or below 300% of the Federal Poverty Level). Application processing takes approximately 2 to 4 weeks.

The National Osteoporosis Foundation and the Bone Health and Osteoporosis Foundation also maintain patient assistance directories. South Dakota's own 211 Helpline can connect patients with local financial navigation resources.

Transferring an Existing Prescription to South Dakota

Patients moving to South Dakota or splitting time between states can transfer an active romosozumab prescription. South Dakota Board of Pharmacy rules permit interstate prescription transfers for non-controlled substances. Romosozumab is not a controlled substance.

The process is straightforward. Contact your current specialty pharmacy and request a transfer to a specialty pharmacy that serves South Dakota. If you are using the buy-and-bill model, your new South Dakota provider will need to submit a new prior authorization under your new insurance (if the plan changed) or contact the existing insurer to update your provider of record.

One complication: if your insurance plan changed during the move, the new plan's formulary and prior authorization criteria may differ. Budget an additional 2 to 3 weeks for a new prior authorization cycle.

Patients on Medicare Part B will find that coverage transfers seamlessly across state lines because Medicare is a federal program. The MAC may change (South Dakota falls under WPS for Part B), but coverage criteria remain the same nationally.

Cardiovascular Safety Considerations

The boxed warning on Evenity's label is based on the ARCH trial, which found a higher rate of adjudicated major adverse cardiovascular events (MACE) in the romosozumab group compared to the alendronate group during the first 12 months (2.5% vs. 1.9%). The absolute difference was 0.6 percentage points.

The FRAME trial, which compared romosozumab to placebo rather than an active comparator, did not show a statistically significant cardiovascular signal (Cosman et al., NEJM 2016). Some researchers have argued the ARCH signal may reflect a protective effect of alendronate rather than harm from romosozumab, but this remains debated.

The practical implication for South Dakota patients: your prescriber must document a cardiovascular risk assessment. Patients with a history of MI or stroke within the prior 12 months should not receive romosozumab. Patients with other cardiovascular risk factors (hypertension, diabetes, hyperlipidemia) are not automatically excluded but should have a risk-benefit discussion documented in the chart. This documentation also satisfies most prior authorization cardiovascular safety requirements.

What Happens After the 12-Month Course Ends

Romosozumab is approved for a single 12-dose course only. Bone density gains achieved during treatment begin to decline if no follow-up anti-resorptive therapy is prescribed. The ARCH trial protocol transitioned patients to alendronate after the romosozumab phase, and this sequential approach maintained and extended the fracture reduction benefit.

The AACE 2020 guidelines recommend transitioning to a bisphosphonate (alendronate or zoledronic acid) or denosumab after completing romosozumab. Abruptly stopping without follow-up therapy risks rapid bone loss, similar to the rebound phenomenon seen with denosumab discontinuation, though less severe.

South Dakota patients should plan the transition before completing dose 12. A follow-up DEXA scan at 12 months helps document treatment response and guides the choice of maintenance therapy. Repeat P1NP and CTX markers can confirm that bone turnover has normalized before switching.